-
-
-
-
-
-
-
Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA® in Coronary Microvascular Dysfunction
-
-
-
-
-
-
-
Caladrius Biosciences to Host First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022, at 4:30 p.m. Eastern Time
-
-
-
-
-
-
-
Caladrius Biosciences to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on Tuesday, March 22, 2022, at 4:30 p.m. Eastern Time
-
-
-
-
-
-
-
Caladrius Biosciences Announces Appointment of Kristen K. Buck, M.D., as Chief Medical Officer
-
-
-
-
-
-
-
Caladrius Biosciences to Assess its CLBS201 CD34+ Cell Therapy in Diabetic Kidney Disease
-
-
-
-
-
-
-
Caladrius Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Caladrius Biosciences, Inc. Announces $65 Million Registered Direct Offerings Priced At-The-Market under Nasdaq Rules
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

